12 Health Care Stocks Moving In Friday's Pre-Market Session
Polaryx Therapeutics, Inc PLYX
$2.31
▲ +7.44%
(+$0.16)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$2.39
Prev Close
$2.15
Day Range
$2.05 – $2.39
52W Range
$1.86 – $48.91
Market Cap
$115.14M
Beta
-2.07
EPS (TTM)
$-0.08
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-02 |
| Shares Out. | 49,850,000 |
| Website | polaryx.com/ ↗ |
| Phone | 12019407236 |
| Net Income | -$2.5M |
| Total Assets | $3.5M |
| Total Liabilities | $1.0M |
| Equity | $2.5M |
About Polaryx Therapeutics, Inc
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Polaryx Therapeutics, Inc is a publicly traded company under the ticker symbol PLYX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)